INTRODUCTION
Hence, there is a strong rationale for exploration of real-life practices in hypertension treatment in these countries and providing evidence for antihypertensive efficacy and tolerability for widely used medications by western populations in these regions.
International hypertension guidelines acknowledge that most patients will require two or more antihypertensive medications to achieve BP control, either as separate agents or in a single pill combination. One of the combinations recommended by the European
Society of Hypertension (ESH)/European
Society of Cardiology (ESC) guidelines is the combination of a calcium channel blocker (CCB) and an angiotensin receptor blocker (ARB). As amlodipine is the most widely prescribed CCB and valsartan is one of the most prescribed ARBs,
we conducted the present study to establish the clinical usefulness, including antihypertensive effectiveness, safety, and tolerability, of their free-dose combination in a real-life outpatient setting across Asia, Egypt, and Russia. 
MATERIALS AND METHODS

Study Design and Procedures
Statistical Analysis
The statistical analysis was performed using 
RESULTS
In total, 2785 patients, prescribed amlodipine/ valsartan in combination by participating physicians, entered the study. From these, only 52 patients (1.9%) discontinued the study and four patient's data was missing/incorrect, therefore 2729 patients were accepted for the final analysis. The reasons for discontinuation of the studied medication are summarized in Table 2 . There was an equal distribution of men and women in the study and the majority of patients were Asian or Caucasian with similar distribution of patients between the two races (Table 3 ). The vast majority of patients (86.5%) received antihypertensive treatment before they were prescribed a combination of amlodipine/ valsartan and the most frequently used medications included angiotensin converting enzyme (ACE) inhibitors, CCB, beta-blockers, and diuretics.
A very small percentage of patients required additional prescription of antihypertensive drugs during the course of the study. In all, 154 patients (5.6%) received beta-blockers and 100 patients (3.7%) received diuretics, concomitantly. These Table 2 . Reasons for discontinuation of study. heart disease (14.6%), diabetes (14.3%), and hypertension (7.0%).
Antihypertensive Efficacy
A total of 2729 patients were analyzed. 
SBP ≥190 mmHg n=257
Grade 3 (SBP ≥180 mmHg) n=593
Grade 2 (SBP 160-179 mmHg) n=1154 Mean BP reduction after 12 weeks of treatment (mmHg) (BP <140/90 mmHg) across the subgroups of patients with hypercholesterolemia, ischemic heart disease, diabetes mellitus, heart failure, and in elderly patients (≥65 years) ( Figure 5 ).
Tolerability
The safety population of our study consisted of 2785 originally enrolled patients. Free-dose combination of amlodipine/valsartan in this 12-week study showed a very low incidence of AEs (8.8% of patients experienced AEs) and only two SAEs were reported, which were not suspected to be related to the studied treatment (Table 4 ). The most common reported AEs were edema, dizziness, and headache with frequency 2.3%, 1.4%, and 1.1%, respectively ( Percentage of patients (%) Figure 4 . Blood pressure control rates. SBP <140 mmHg and DBP <90 mmHg Percentage of patients (%) Figure 5 . Blood pressure control rates in subgroups of patients.
Subdural hemorrhage and pneumonia were the two SAEs reported during this study. Both SAEs resulted in death and both were not suspected to be related to the study medication. Out of these two SAEs, subdural hemorrhage was reported after the patient had already discontinued the study drug due to different AEs that happened earlier, so the death of this patient is not included in Table 2 .
As edema is considered the most frequent and specific AE of CCB, we conducted an in-depth analysis of this event in our study. Out of 2729 patients, 13.7% patients experienced edema at baseline in visit 1, 12% patients had edema at visit 2, 10.7% at visit 3, and 10.1% at (Table 6 ). The most interesting is the frequency of edema for the 10/160 mg dosing regimen.
The baseline incidence of edema in this group was twice as high as in the general population or other subgroups of patients (25.4%), but it also decreased at the end of the study (17.3%).
Although the CCB-caused edema could still be present in some patients at the end of our study, the use of amlodipine/valsartan in combination reduced the frequency of edema by 26.6% and the severity of edema was also reduced in our observational study. The reduction in edema frequency was the greatest in patients treated with a constant dose of 5/160 mg amlodipine/ valsartan (-56.4%), followed by 5/80 mg (-40.7%), and 10/160 mg dosing regimens (-31.8%).
DISCUSSION
Our study demonstrated that amlodipine/ valsartan in combination significantly reduces BP in patients with arterial hypertension. The BP lowering effect was dose dependant and also corresponded to the baseline level of BP elevation. These results were achieved during 12 weeks of treatment and a very small number of AEs and SAEs were detected in a large cohort of 2785 hypertension patients. Another interesting finding in our study is that no increase in heart rate was observed, providing evidence that there was no influence of amlodipine in combination with valsartan on heart rate as one could expect.
The in-depth analysis of peripheral edema incidence also showed attenuation of this wellknown side effect of CCB by the addition of ARB and this tendency was evident for almost all dosing regiments of such combination.
The results of our study correspond well to In our study we can also find evidence of such efficacy if we look at the previous hypertension medication data. Originally, 86.5% of our enrolled patients were receiving antihypertensive medication before they were prescribed amlodipine/valsartan in combination.
If we sum up the shares of different original medication classes (Table 3) show that the incidence of diagnosed edema at baseline (13.7%) was not increased, which one could expect when all patients were prescribed amlodipine, but even decreased by 26.5% at the study end. The reduction of severe edema cases shown for all studied dosing regimens once again proves the good tolerability profile of the combination.
And finally, the very low incidence of all other AEs, with incidence of dizziness and headache less than 2% add much information to the reallife tolerability of the amlodipine/valsartan combination. Another measure of amlodipine/ valsartan combination efficacy and tolerability in our study is the fact that 93.5% patients were due to have their prescription continued after the completion of the study period.
Limitations
Our study has an obvious limitation of being a nonrandomized, noncontrolled, observational study, which may limit the interpretation of our results. The real-life setting of our study does not allow us to make solid conclusions concerning comparative efficacy and tolerability of the studied combination. The subjective evaluation of edema frequency and severity is also a limitation for our study. However, the observational design of this study made it possible to acquire a large amount of data in a broad population of hypertensive patients, which makes the results of this study more relevant to real-life clinical practice. 
